Free Trial

20 Stocks Wall Street Analysts Love the Most - 7 of 20

 
 

Clean Harbors (NYSE:CLH)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$242.40 (0.1% Downside)

About Clean Harbors

Clean Harbors logoClean Harbors, Inc provides environmental and industrial services in the United States and internationally. The company operates through two segments, Environmental Services and Safety-Kleen Sustainability Solutions. The Environmental Services segment collects, transports, treats, and disposes hazardous and non-hazardous waste, such as resource recovery, physical treatment, fuel blending, incineration, landfill disposal, wastewater treatment, lab chemicals disposal, and explosives management services; and offers CleanPack services, including collection, identification, categorization, specialized packaging, transportation, and disposal of laboratory chemicals and household hazardous waste. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
8/1/2024Needham & Company LLCBoost Price TargetBuy ➝ Buy$235.00 ➝ $274.00
8/1/2024The Goldman Sachs GroupBoost Price TargetNeutral ➝ Neutral$223.00 ➝ $256.00
8/1/2024OppenheimerBoost Price TargetOutperform ➝ Outperform$245.00 ➝ $252.00
8/1/2024Stifel NicolausReiterated RatingBuy ➝ Buy$240.00 ➝ $275.00
8/1/2024Robert W. BairdBoost Price TargetOutperform ➝ Outperform$242.00 ➝ $268.00
7/11/2024Truist FinancialBoost Price TargetBuy ➝ Buy$240.00 ➝ $260.00
5/3/2024Truist FinancialBoost Price TargetBuy ➝ Buy$210.00 ➝ $240.00
5/2/2024Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$225.00 ➝ $235.00
5/2/2024BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$225.00 ➝ $230.00
5/2/2024Robert W. BairdBoost Price TargetOutperform ➝ Outperform$235.00 ➝ $240.00
 

Revolutionary Tech Alert: How Elon Musk is Changing Lives (Ad)

"Elon Musk's Neuralink just received FDA breakthrough status for a revolutionary device designed to restore vision to those who've lost it entirely. And the first human clinical trials have opened for recruitment.

Click here to see it.